Company news

Werewolf Therapeutics, Inc. news in 2024

Werewolf Therapeutics, Inc.'s news releases, calls and decks from 2024, newest first.

View company

Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

November 6, 2024

Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases

October 30, 2024

Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

August 7, 2024

Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma

June 24, 2024

Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors

May 31, 2024

Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

May 2, 2024

Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

April 23, 2024

Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting

April 22, 2024

Werewolf Therapeutics Presents Preclinical Results Demonstrating Anti-Tumor Effects of Pro-Inflammatory Cytokine Therapeutics WTX-518 and WTX-712 at AACR 2024 Annual Meeting

April 4, 2024

Werewolf Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

March 6, 2024

Werewolf Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2024

March 4, 2024

Werewolf Therapeutics Provides Business Update and Highlights 2024 Strategic Outlook

January 7, 2024

Werewolf Therapeutics Appoints Michael Atkins, M.D., to its Board of Directors

January 3, 2024

Decks in 2024